Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). DTT 08-02
FI: 2,769
Type: Article
Collaboration
Year: 2015
Writers
Rivera, F; Massuti, B; Salcedo, M; Tailor, J; Galan, JM; Valladares-Ayerbes, M; Serrano, R; de Paredes, MLG; Manzano, JL; Galan, M; Alsina, M; Left, ALY; Lopez, C; Diaz-Rubio, E; Count, V; Reboredo, M; Cano, MT; Pachon, V; Aranda, E
Magazine
Title: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Quartile
- Q2